Skip to content

Theravance Biopharma, Inc.

Delisted

CIK 1583107fmd_0MR32M6JM5P545CNWXKG60X71DManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2012 to Jun 30, 2026, 55 periods

Latest annual · FY2025

Millions
Total revenues
107
Operating income
(4)
Net income
106
Free cash flow
238

Latest quarter · Q2 FY2026

Millions
Total revenues
21
Operating income
(8)
Net income
(6)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2022 to FY2025
+27.9%
Revenue, 5 yearsFY2020 to FY2025
+8.4%
Net income, 5 yearsFY2020 to FY2025
n/m

Theravance Biopharma, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2025FY2024ChangeSource
Revenue$107.5 million$64.4 million+66.9%10-K 2026-03-23 · proof
Operating income-$3.6 million-$46.9 million10-K 2026-03-23 · proof
Net income$105.9 million-$56.4 million10-K 2026-03-23 · proof
Cash from operating activities$238.5 million-$11.5 million10-K 2026-03-23 · proof
Free cash flow$238.5 million-$11.9 million10-K 2026-03-23 · proof
Total assets$485.6 million$354.2 million+37.1%10-K 2026-03-23 · proof
Total liabilities$188.8 million$178.6 million+5.7%10-K 2026-03-23 · proof
Cash and cash equivalents$167.8 million$37.8 million+344%10-K 2026-03-23 · proof
What was Theravance Biopharma, Inc.'s revenue in fiscal 2025?
Theravance Biopharma, Inc. reported revenue of $107.5 million for fiscal 2025 (the year ended Dec 31, 2025), against $64.4 million the year before (+66.9%). Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
What was Theravance Biopharma, Inc.'s operating income in fiscal 2025?
Theravance Biopharma, Inc. reported operating income of -$3.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$46.9 million the year before. Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
What was Theravance Biopharma, Inc.'s net income in fiscal 2025?
Theravance Biopharma, Inc. reported net income of $105.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$56.4 million the year before. Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
What was Theravance Biopharma, Inc.'s cash from operating activities in fiscal 2025?
Theravance Biopharma, Inc. reported cash from operating activities of $238.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$11.5 million the year before. Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
What was Theravance Biopharma, Inc.'s free cash flow in fiscal 2025?
Theravance Biopharma, Inc. reported free cash flow of $238.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$11.9 million the year before. Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
What are Theravance Biopharma, Inc.'s total assets?
As of Dec 31, 2025, Theravance Biopharma, Inc. reported total assets of $485.6 million, against $354.2 million a year earlier (+37.1%). Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
What are Theravance Biopharma, Inc.'s total liabilities?
As of Dec 31, 2025, Theravance Biopharma, Inc. reported total liabilities of $188.8 million, against $178.6 million a year earlier (+5.7%). Source: the 10-K filed with the SEC on Mar 23, 2026. SEC
What are Theravance Biopharma, Inc.'s cash and cash equivalents?
As of Dec 31, 2025, Theravance Biopharma, Inc. reported cash and cash equivalents of $167.8 million, against $37.8 million a year earlier (+344%). Source: the 10-K filed with the SEC on Mar 23, 2026. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1583107&period_type=annual&limit=5"

Information only, not investment advice.